Effect of 12-week continuous ingestion of the supplement on liver function.-A placebo-controlled, randomized, double-blind, parallel-group comparative study

Not Applicable

• Conditions: Healthy adults

• Registration Number: JPRN-UMIN000044495
• Lead Sponsor: KSO Corporation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-11
• Study Completion: 2021-11-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects whose AST is above 50 U/L and/or Gamma-GTP above 100 U/L at the time of the screening test 2. 2.Subjects who have history of liver disease, or is currently under medical treatment of the liver disease. 3.Subjects who are suffering or suffered from serious disease in the past. 4.Subjects who have average intake of alcohol more than 59 g per week. 5.Subjects who have food allergies or who may be allergic to the test food. 6.Subjects who are taking drugs and quasi-drugs that may affect the current study. 7.Subjects who are taking health foods that may affect the current study. 8.Subjects who cannot stop taking the drugs, quasi-drugs and health foods during the study period (after agreeing to the informed consent until the end of the 12-week test food ingestion period). 9.Subjects who have extremely irregular lifestyles. 10.Subjects who are currently participating in other studies, or participating in other studies within the past 3 months from the time of the informed consent. 11.Subjects who are planning to participate in other studies during this study. 12.Subjects who are pregnant, or planning to become pregnant or breastfeed during this study. 13.Subjects who are judged as unsuitable participant for the study by the doctor and investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified